Literature DB >> 14580047

Albumin administration--what is the evidence of clinical benefit? A systematic review of randomized controlled trials.

G R Haynes1, R J Navickis, M M Wilkes.   

Abstract

BACKGROUND AND
OBJECTIVE: The advantages of albumin over less costly alternative fluids continue to be debated. Meta-analyses focusing on survival have been inconclusive, and other clinically relevant end-points have not been systematically addressed. We sought to determine whether albumin confers significant clinical benefit in acute illness compared with other fluid regimens.
METHODS: Database searches (MEDLINE, EMBASE, Cochrane Library) and other methods were used to identify randomized controlled trials comparing albumin with crystalloid, artificial colloid, no albumin or lower-dose albumin. Major findings for all end-points were extracted and summarized. A quantitative meta-analysis was not attempted.
RESULTS: Seventy-nine randomized trials with a total of 4755 patients were included. No significant treatment effects were detectable in 20/79 (25%) trials. In cardiac surgery, albumin administration resulted in lower fluid requirements, higher colloid oncotic pressure, reduced pulmonary oedema with respiratory impairment and greater haemodilution compared with crystalloid and hydroxyethylstarch increased postoperative bleeding. In non-cardiac surgery, fluid requirements, and pulmonary and intestinal oedema were decreased by albumin compared with crystalloid. In hypoalbuminaemia, higher doses of albumin reduced morbidity. In ascites, albumin reduced haemodynamic derangements, morbidity and length of stay and improved survival after spontaneous bacterial peritonitis. In sepsis, albumin decreased pulmonary oedema and respiratory dysfunction compared with crystalloid, while hydroxyethylstarch induced abnormalities of haemostasis. Complications were lowered by albumin compared with crystalloid in burn patients. Albumin-containing therapeutic regimens improved outcomes after brain injury.
CONCLUSIONS: Albumin can bestow benefit in diverse clinical settings. Further trials are warranted to delineate optimal fluid regimens, in particular indications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580047     DOI: 10.1017/s0265021503001273

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  23 in total

1.  Why albumin may still work.

Authors:  Johan Groeneveld
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

2.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

3.  The effects of lactated Ringer's solution (LRS) or LRS and 6% hetastarch on the colloid osmotic pressure, total protein and osmolality in healthy horses under general anesthesia.

Authors:  Erin L Wendt-Hornickle; Lindsey B C Snyder; Rui Tang; Rebecca A Johnson
Journal:  Vet Anaesth Analg       Date:  2011-06-01       Impact factor: 1.648

Review 4.  In my opinion: serum albumin should be maintained during neurocritical care.

Authors:  David J Powner
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

Review 5.  Perioperative nutritional support and fluid therapy in patients with liver diseases.

Authors:  Yongliang Sun; Zhiying Yang; Haidong Tan
Journal:  Hepatobiliary Surg Nutr       Date:  2014-06       Impact factor: 7.293

6.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 7.  [State of the art in fluid and volume therapy : A user-friendly staged concept].

Authors:  M Rehm; N Hulde; T Kammerer; A S Meidert; K Hofmann-Kiefer
Journal:  Anaesthesist       Date:  2017-03       Impact factor: 1.041

8.  Serum albumin level accurately reflects antioxidant potentials in idiopathic nephrotic syndrome.

Authors:  Kazunari Kaneko; Takahisa Kimata; Shoji Tsuji; Tomohiko Shimo; Masaya Takahashi; Sachiyo Tanaka
Journal:  Clin Exp Nephrol       Date:  2011-12-28       Impact factor: 2.801

9.  State of the art in fluid and volume therapy : A user-friendly staged concept. English version.

Authors:  M Rehm; N Hulde; T Kammerer; A S Meidert; K Hofmann-Kiefer
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

10.  A case of cell-free and concentrated ascites reinfusion therapy effective for refractory ascites in spontaneous bacterial peritonitis in a renal transplant patient.

Authors:  Atsuhiro Maeda; Kazuhito Takeda; Kazuhiko Tsuruya; Shuuhei Miura; Jirou Toyonaga; Satsuki Nakashita; Masahide Furushou; Hideyuki Mukai; Yoshiharu Mutou; Tomo Komaki; Keita Takae; Chikao Yasunaga
Journal:  Case Rep Nephrol Urol       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.